Date: 2012-11-05
Type of information: Fundraising
Company: Ziarco (UK)
Investors: Biotechnology Value Fund L.P. (USA) and other affiliates of BVF Partners L.P. (USA) - Pfizer Venture Investments (USA)
Amount: undisclosed
Funding type: series A financing round
Planned used: Proceeds from the funding will be invested to advance the research and development of novel therapeutic agents to address inflammatory and allergic diseases.
Others: Ziarco, a newly created clinical-stage biotechnology company, has completed a Series A financing. In addition, Ziarco has entered into an agreement with Pfizer for the exclusive worldwide rights to commercialize a portfolio of clinical, preclinical and research assets. In return, Pfizer will receive equity as well as certain product-based milestone and royalty payments.
Ziarco is founded by Dr Mike Yeadon, President and CEO, formerly Vice President and Chief Scientific Officer of Pfizer’s Allergy and Respiratory Research Unit, and three former Pfizer colleagues, Dr Steve Liu, Vice President and Chief Scientific Officer, Dr Lynn Purkins, Vice President and Head Clinical Development, and Dr Arif Shivji, Vice President and Head Development Operations and Business Development.
Ziarco’s pipeline includes a histamine H4 receptor antagonist programme, with a lead compound that has completed a Phase 1 multiple ascending dose study; a clinical stage cytosolic phosholipase A2 (cPLA2) inhibitor; histamine H3 receptor antagonists possessing CNS-sparing properties, with a lead compound in advanced preclinical development; as well as early-stage spleen tyrosine kinase (SYK) inhibitor molecules suitable for topical administration.
Therapeutic area:
